

PRESS RELEASE

28 January 2015 – Veryan Medical has announced a distribution agreement with Biosensors International for BioMimics 3D™, its Nitinol stent with unique three-dimensional helical geometry for treatment of the femoropopliteal artery. The agreement covers certain international markets but excludes the USA and Japan.

The BioMimics 3D stent incorporates Veryan’s patented 3D helical technology, an advanced stent design that promotes natural swirling blood flow to elevate wall shear stress, which has been shown to reduce neointimal hyperplasia. The 3D advanced design has also been shown to improve the biomechanical performance of the stent when implanted in the femoropopliteal artery, mitigating the risk of stent fracture and vessel kinking.

Recently-presented two-year data from the Mimics study have confirmed that BioMimics 3D provides a significant improvement in long-term patency compared to a straight Nitinol control stent in patients undergoing femoropopliteal artery intervention. The data indicate a correlation between primary patency and stent curvature. This important, randomised study shows a clear clinical benefit of the BioMimics 3D technology over the control - straight Nitinol stents.

In a press release from BioSensors International Group, CEO Jose Calle commented “We are delighted to have secured this important distribution agreement with Veryan for BioMimics 3D. This innovative device will complement our portfolio of products in the area of peripheral arterial disease”. Veryan Chief Executive Chas Taylor added. “With their established expertise in coronary stenting, growing presence in the area of peripheral arterial disease and with

established sales forces in major markets, Biosensors is an excellent partner to effectively promote our BioMimics 3D helical stent technology, we look forward to a successful relationship and we expect to commence active promotion of BioMimics 3D in the immediate future”.

-Ends-

Media contact:

Richard Kenyon
richard@rkpr.co.uk
+44 7831 569940

About Veryan Medical Ltd.

Veryan is developing innovative solutions to improve the performance of vascular stents using the principles of biomimicry. Veryan’s BioMimics 3D® stent technology involves adapting traditional straight stent designs to a patented three-dimensional helical shape, which more closely mimics the natural geometry of the human vascular system. BioMimics 3D technology is designed to enhance clinical performance by improving flow conditions in, and biomechanical performance of, stented vessels. The advanced, biomimetic design of the BioMimics 3D stent is intended to provide more flexibility, kink and fracture resistance than other laser-cut Nitinol tube stents, making its unique design of particular importance in the hostile environment of the femoropopliteal artery. Veryan’s Research & Development facility is located in Galway, Ireland.

BioMimics 3D is a registered trademark of Veryan Medical Ltd.

CAUTION: The BioMimics 3D stent is not available for sale or investigational use in the United States.

For further information, please visit: www.veryanmed.com